SSY Group (HKG:2005) expects a decline of between 45% and 60% in attributable profit for the year 2025 from HK$1.06 billion a year prior, according to a Monday Hong Kong bourse filing.
The pharmaceutical firm attributed the forecast to a lower terminal sales volume of medicines, continuing price pressure, and a drop in the turnover of Bromhexine Hydrochloride in ampoule injection.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.